WYETH: Neurome and Wyeth are working together
in this collaboration to investigate a number of aspects of
CNS disease, beginning with the comprehensive evaluation and
morphological analysis of one of Wyeth’s transgenic
animal models of Alzheimer’s disease used to evaluate
selected preclinical compounds. Employing its proprietary
technologies and expertise in quantitative neuropathology,
Neurome will assist Wyeth in its Discovery Research efforts
involving treatment of Central Nervous System (CNS) disorders.
Neurome’s extensive experience with animal models of
CNS diseases and proprietary technologies will allow it to
derive quantitative 3-D information, including volumetric
analysis, on these animals. Under the terms of the multi-year
agreement, Neurome receives research funding from Wyeth.
La Jolla Pharmaceutical Company: The collaboration
is focused on the investigation of proteins in the brain that
selectively bind antibodies to double-stranded DNA found in
patients with systemic lupus erythematosus (lupus). In combination
with La Jolla Pharmaceutical Company’s experience in
discovering and developing innovative therapeutics to treat
the underlying causes of antibody-mediated diseases, the Neurome
Technologies will be used to provide La Jolla Pharmaceutical
with information on potential targets in the Central Nervous
System (CNS) affected by lupus.
Elan Corporation, plc.: The research partnership
with Elan has an initial term of 3 years and may generate
up to $4 million in service revenue for Neurome, together
with shared ownership of the diagnostic and therapeutic applications
of the genes, circuits and mechanisms identified in the research.
The partnership will utilize Neurome's technologies to analyze
a mouse model of Alzheimer's Disease with the goal of identifying
and exploiting molecules and pathways relevant to diagnosis
and treatment of the disease. The partnership will analyze
Elan's proprietary mouse model of amyloid deposition in an
attempt to answer a variety of scientific questions regarding
ImClone Systems Incorporated: This partnership
focuses on early-stage discovery investigation of preclinical
antibody candidate molecules. Neurome is providing ImClone
Systems with qualitative and quantitative information on the
effects of selected preclinical antibody molecules on potential
drug targets in the Central Nervous System whose corresponding
behavioral effects suggest potential therapeutic mechanisms
are at work.
Merck Research Labs: Neurome is applying
its suite of proprietary technologies in ongoing collaboration
with Merck to reveal new insights into to mechanisms underlying
Central Nervous System disease.
PsychoGenics Inc.: Neurome has partnered
with PsychoGenics Inc. to work together to develop better
predictive test systems, along with specific biological markers
for drug target expression patterns, that will enable pharmaceutical
companies looking to screen new chemical entities for depression
to obtain reliable behavioral readouts and their corresponding
neurobiological, gene- or protein- expression signatures.
An improved predictive test regiment will aid in the acceleration
of the discovery and development of drugs to treat depression.
This partnership is being carried out under a National Institutes
of Health (NIH) Small Business Innovation Research (SBIR)